Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis-Reference-Cited by-同舟云学术

Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis

Published:2019-12-13 Issue:4 Volume:27 Page:371-375
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Boyle Alison¹²^ORCID,Marra Fiona¹²,Peters Erica³,Datta Shouren⁴,Ritchie Trina⁵,Priest Matthew⁶,Heydtmann Mathis⁷,Barclay Stephen T.⁸⁹^ORCID

Affiliation:

1. Department of Pharmacy NHS Greater Glasgow and Clyde Glasgow UK

2. Department of Molecular and Clinical Pharmacology Institute of Translational Medicine University of Liverpool Liverpool UK

3. Department of Infectious Diseases Queen Elizabeth University Hospital NHS Greater Glasgow and Clyde Glasgow UK

4. Department of Gastroenterology Queen Elizabeth University Hospital NHS Greater Glasgow and Clyde Glasgow UK

5. Glasgow Alcohol and Drug Services NHS Greater Glasgow and Clyde Glasgow UK

6. Department of Gastroenterology Gartnavel General Hospital NHS Greater Glasgow and Clyde Glasgow UK

7. Department of Gastroenterology Royal Alexandra Hospital NHS Greater Glasgow and Clyde Glasgow UK

8. Department of Gastroenterology Glasgow Royal Infirmary NHS Greater Glasgow and Clyde Glasgow UK

9. Department of Life Sciences Glasgow Caledonian University Glasgow UK

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13239

Reference15 articles.

1. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

2. Once daily Sofosbuvir with GS‐5816 for 8 Weeks with or without ribavirin in patients with HCV Genotype 3 without cirrhosis result in high rates of SVR12: the ELECTRON2 Study;Gane EJ;Hepatology,2014

3. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection

4. SMC 2016. “Scottish Medicines Consortium Advice on Sofosbuvir‐Velpatasvir (Epclusa)”.https://www.scottishmedicines.org.uk/. July 11 2016.https://www.scottishmedicines.org.uk/medicines-advice/sofosbuvirvelpatasvir-epclusa-fullsubmission-119516/. Accessed June 6 2018.

5. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024;Saudi Journal of Gastroenterology;2024-01

2. Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial);PLOS ONE;2023-05-18

3. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study;eLife;2023-01-09

4. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for Hepatitis C: a single arm mechanistic pilot study;2022-08-17

5. Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy;PLOS ONE;2021-06-04